As the indications for recombinant human growth hormone (r-hGH) treatment have expanded, the number of patients receiving r-hGH has increased and injectable delivery of r-hGH is likely to be required for the foreseeable future. Continued innovations in the ease of use, safety and reliability of r-hGH devices have already gone some way to making GH treatment less stressful for patients, both physically and psychologically. Adherence with r-hGH remains a problem, which may be alleviated by offering free patient choice. In addition development of electronic auto-injectors now also provides the potential for monitoring adherence both for healthcare professionals, and also aiding patients in administering and monitoring their own GH injections.
Keywords: Growth hormone, easypod, Growth hormone deficiency, somatropin
Rights & PermissionsPrintExport